Contact allergy to neomycin in consecutively patch tested Danish eczema patients from 2000 to 2023: A cross‐sectional study
Contact Dermatitis · 2024
DOI: 10.1111/cod.14653 ↗Kurz gefasst
Fachartikel in der Zeitschrift Contact Dermatitis, 2024. Verfasst von Christoffer Kursawe Larsen und 2 weiteren Autor:innen. Beteiligte Einrichtung: National Allergy Research Centre, Department of Dermatology and Allergy, Herlev and Gentofte Hospital, Hellerup, Denmark. Hauptthemen laut MEDLINE: Neomycin, Dermatitis, Allergic Contact, Patch Tests. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Danish Environmental Protection Agency under the Ministry of Environment of Denmark.
Abstract (Originalsprache)
Background
Neomycin is an aminoglycoside antibiotic that may cause contact allergy. It was withdrawn as a medicine for human use in Denmark in October 2009 but is still found in some vaccines.
Objectives
To identify time trends in contact allergy to neomycin in the period from 2000 to 2023.
Methods
A cross‐section study of patients ≥18 years consecutively patch‐tested with neomycin sulfate (20% in pet.) at Gentofte Hospital, Denmark, during the period 2000–2023 was conducted.
Results
The overall prevalence of contact allergy to neomycin was 1.4%. The prevalence was significantly lower in the period ‘2010–2023’ (1.2%) than in ‘2000–2009’ (1.8%) ( p < 0.005). Contact allergy to neomycin was significantly positively associated with facial dermatitis and age >40 years, and significantly negatively associated with occupational dermatitis and hand dermatitis. No changes in sex, occupational dermatitis, atopic dermatitis, hand dermatitis, leg dermatitis, facial dermatitis, or age > 40/≤40 (the MOAHLFA‐index) were identified when comparing neomycin contact allergic‐patients in the two periods ‘2010–2023’ and ‘2001–2009’.
Conclusion
Neomycin is a rare cause of contact allergy in Denmark with a significantly lower prevalence following its withdrawal as a medicinal product for human use in Denmark in 2009.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Allergy Research Centre, Department of Dermatology and Allergy, Herlev and Gentofte Hospital, Hellerup, Denmark.
- Faculty of Health Science, Institute of Clinical Medicine, University of Copenhagen, Denmark.
- Department of Dermatology and Allergy, Herlev and Gentofte Hospital, Hellerup, Denmark.
ORCID-Profile: Christoffer Kursawe Larsen, Mikkel Bak Jensen, Jakob F B Schwensen
Förderung
- Danish Environmental Protection Agency under the Ministry of Environment of Denmark
Zitieren
APA
Kursawe Larsen, C., Jensen, M. B., & Schwensen, J. F. B. (2024). Contact allergy to neomycin in consecutively patch tested Danish eczema patients from 2000 to 2023: A cross‐sectional study. Contact Dermatitis. https://doi.org/10.1111/cod.14653
Vancouver
Kursawe Larsen C, Jensen MB, Schwensen JFB. Contact allergy to neomycin in consecutively patch tested Danish eczema patients from 2000 to 2023: A cross‐sectional study. Contact Dermatitis. 2024. doi:10.1111/cod.14653
BibTeX
@article{KursaweLarsen2024,
author = {Kursawe Larsen, Christoffer and Jensen, Mikkel Bak and Schwensen, Jakob F B},
title = {Contact allergy to neomycin in consecutively patch tested Danish eczema patients from 2000 to 2023: A cross‐sectional study},
journal = {Contact Dermatitis},
year = {2024},
doi = {10.1111/cod.14653}
}
EUVIMED